Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NYSE:BMY

Bristol Myers Squibb Q3 2026 Earnings Report

Bristol Myers Squibb logo
$62.65 -0.21 (-0.33%)
Closing price 09/30/2026 03:59 PM Eastern
Extended Trading
$62.95 +0.29 (+0.47%)
As of 09/30/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Bristol Myers Squibb EPS Results

Actual EPS
N/A
Consensus EPS
$1.68
Beat/Miss
N/A
One Year Ago EPS
N/A

Bristol Myers Squibb Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.62 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bristol Myers Squibb Announcement Details

Quarter
Q3 2026
Date
10/29/2026
Time
Before Market Opens
Conference Call Date
Thursday, October 29, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Bristol Myers Squibb Earnings Headlines

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic ...
September 30 at 6:51 PM  |  marketscreener.comM
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
September 30 at 5:32 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260930516104/en/u.s.-food-and-drug-administration-approves-expanded-indication-for-bristol-myers-squibb%e2%80%99s-camzyos%c2%ae-mavacamten-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm-in-adults-and-pediatric-patients*/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
September 30 at 1:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/investors-heavily-search-bristol-myers-120003022.html
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric
September 30 at 1:50 PM  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/bristol-myers-squibbs-dividend-sustainability-hinges-on-one-critical-cash-flow-metric/
BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea
September 30 at 12:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bmy-expands-real-world-cancer-data-with-new-augtyro-study-in-korea?utm_source=marketbeat.com&utm_medium=referral
See More Bristol Myers Squibb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bristol Myers Squibb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bristol Myers Squibb and other key companies, straight to your email.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors. Its newer and specialized products include Breyanzi, a cell therapy for certain blood cancers; Camzyos, a cardiovascular medicine; and Sotyktu, an immunology treatment. The company also develops investigational therapies through internal research and collaborations.

The company traces its history to the formation of Bristol-Myers in 1889 and the founding of the E.R. Squibb & Sons pharmaceutical business in 1858. Bristol-Myers Squibb was created through the 1989 merger of the two companies. Its corporate headquarters are in Princeton, New Jersey. Christopher Boerner has served as chief executive officer since November 2023.

View Bristol Myers Squibb Profile
Earnings Tools